Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. more
Time Frame | CNTA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -11.25% | -2.27% | -0.57% |
1-Month Return | -8.35% | -3.96% | 1.21% |
3-Month Return | -2.47% | -9.7% | 7.57% |
6-Month Return | 66.87% | -3.37% | 11.45% |
1-Year Return | 149.17% | 3.71% | 28.48% |
3-Year Return | 35.27% | 3.8% | 29.52% |
5-Year Return | -23.82% | 39.78% | 90.66% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 6.85M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | - | 33.99K | 130.92K | 786.58K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":4.32,"profit":true},{"date":"2022-12-31","value":16.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | - | (33.99K) | (130.92K) | 6.85M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.5,"profit":false},{"date":"2022-12-31","value":-1.91,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | - | - | - | 100.00% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 5.05M | 10.44M | 139.28M | 210.28M | 178.14M | [{"date":"2019-12-31","value":2.4,"profit":true},{"date":"2020-12-31","value":4.96,"profit":true},{"date":"2021-12-31","value":66.23,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.71,"profit":true}] |
Operating Income | (5.05M) | (10.44M) | (139.31M) | (212.26M) | (171.28M) | [{"date":"2019-12-31","value":-505300000,"profit":false},{"date":"2020-12-31","value":-1044000000,"profit":false},{"date":"2021-12-31","value":-13931440000,"profit":false},{"date":"2022-12-31","value":-21226300000,"profit":false},{"date":"2023-12-31","value":-17128300000,"profit":false}] |
Total Non-Operating Income/Expense | (121.00K) | (601.00K) | - | (11.72M) | (6.82M) | [{"date":"2019-12-31","value":-12100000,"profit":false},{"date":"2020-12-31","value":-60100000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-1172400000,"profit":false},{"date":"2023-12-31","value":-681500000,"profit":false}] |
Pre-Tax Income | (5.06M) | (10.66M) | (381.74M) | (216.95M) | (176.14M) | [{"date":"2019-12-31","value":-506100000,"profit":false},{"date":"2020-12-31","value":-1066300000,"profit":false},{"date":"2021-12-31","value":-38174051100,"profit":false},{"date":"2022-12-31","value":-21695400000,"profit":false},{"date":"2023-12-31","value":-17614100000,"profit":false}] |
Income Taxes | 223.00K | 378.00K | 113.99K | (747.00K) | (25.06M) | [{"date":"2019-12-31","value":58.99,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":30.16,"profit":true},{"date":"2022-12-31","value":-197.62,"profit":false},{"date":"2023-12-31","value":-6628.57,"profit":false}] |
Income After Taxes | (5.28M) | (11.04M) | - | (216.21M) | (151.09M) | [{"date":"2019-12-31","value":-528400000,"profit":false},{"date":"2020-12-31","value":-1104100000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-21620700000,"profit":false},{"date":"2023-12-31","value":-15108500000,"profit":false}] |
Income From Continuous Operations | (5.06M) | (10.66M) | - | (216.21M) | (157.42M) | [{"date":"2019-12-31","value":-506100000,"profit":false},{"date":"2020-12-31","value":-1066300000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-21620700000,"profit":false},{"date":"2023-12-31","value":-15742100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (5.28M) | (11.04M) | (381.85M) | (216.21M) | (151.09M) | [{"date":"2019-12-31","value":-528400000,"profit":false},{"date":"2020-12-31","value":-1104100000,"profit":false},{"date":"2021-12-31","value":-38185449800,"profit":false},{"date":"2022-12-31","value":-21620700000,"profit":false},{"date":"2023-12-31","value":-15108500000,"profit":false}] |
EPS (Diluted) | - | (4.97) | (1.90) | (2.31) | (1.57) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-496.85,"profit":false},{"date":"2021-12-31","value":-190,"profit":false},{"date":"2022-12-31","value":-231,"profit":false},{"date":"2023-12-31","value":-157,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CNTA | |
---|---|
Cash Ratio | 19.63 |
Current Ratio | 21.52 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CNTA | |
---|---|
ROA (LTM) | -20.47% |
ROE (LTM) | -42.52% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CNTA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CNTA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 330.53 |
P/B | 4.54 |
Price/FCF | NM |
EV/R | 267.24 |
EV/Ebitda | 1.12 |
Centessa Pharmaceuticals PLC ADR (CNTA) share price today is $16.57
Yes, Indians can buy shares of Centessa Pharmaceuticals PLC ADR (CNTA) on Vested. To buy Centessa Pharmaceuticals PLC ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CNTA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Centessa Pharmaceuticals PLC ADR (CNTA) via the Vested app. You can start investing in Centessa Pharmaceuticals PLC ADR (CNTA) with a minimum investment of $1.
You can invest in shares of Centessa Pharmaceuticals PLC ADR (CNTA) via Vested in three simple steps:
The 52-week high price of Centessa Pharmaceuticals PLC ADR (CNTA) is $18.97. The 52-week low price of Centessa Pharmaceuticals PLC ADR (CNTA) is $6.65.
The price-to-earnings (P/E) ratio of Centessa Pharmaceuticals PLC ADR (CNTA) is
The price-to-book (P/B) ratio of Centessa Pharmaceuticals PLC ADR (CNTA) is 4.54
The dividend yield of Centessa Pharmaceuticals PLC ADR (CNTA) is 0.00%
The market capitalization of Centessa Pharmaceuticals PLC ADR (CNTA) is $2.27B
The stock symbol (or ticker) of Centessa Pharmaceuticals PLC ADR is CNTA